Shenzhen Minkave Technology (300506.SZ) intends to acquire no more than 26.19% of the shares of solid-state storage solutions provider Zhiyu Technology.
Mingjiahui (300506.SZ) issued an announcement stating that the company intends to purchase no more than 26.1904% (inclusive) of shares in Zhiyu Technology Co., Ltd. (referred to as "Zhiyu Technology") for cash, with the total transaction price estimated at approximately 263 million yuan.
Shenzhen Minkave Technology (300506.SZ) announced that the company intends to purchase no more than 26.1904% (inclusive) of the shares of Zhiyu Technology Co., Ltd. (referred to as "Zhiyu Technology") in cash, with an estimated total transaction value of approximately 263 million yuan.
It is reported that the company's existing main business is landscape lighting engineering, which includes the design, construction, and related research, development, and sales of lighting products. The target company is a solid-state storage solution provider that integrates research and development, production, sales, and service. Zhiyu Technology focuses on solid-state drive products, primarily targeting the industrial-grade storage market. The main products of the target company include solid-state drives (SSDs), embedded SSDs, and media cards. The company aims to achieve a strategic layout in the semiconductor industry and realize diversified and sustainable development through this transaction.
Related Articles

US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.

NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.

EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.

NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.

EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.

RECOMMEND





